Loading...
Back to narrative

ACUTAAS: Upcoming Board Meeting And Margins Will Shape Near-Term Outlook

Update shared on 02 Dec 2025

n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
55.6%
7D
-1.7%

Analysts have maintained their price target for Acutaas Chemicals at $1,831.50. They cite consistent projections in revenue growth and profit margins as key factors supporting this unchanged outlook.

What's in the News

  • A board meeting is scheduled for October 17, 2025, at 11:00 Indian Standard Time to approve the unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025 (Key Developments).

Valuation Changes

  • Consensus Analyst Price Target remains unchanged at ₹1,831.50.
  • Discount Rate is stable at 12.76%.
  • Revenue Growth projection holds steady at 33.16%.
  • Net Profit Margin is unchanged at 23.44%.
  • Future P/E ratio shows no change and remains at 38.93x.

Have other thoughts on Acutaas Chemicals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.